Laboratory studies that led to the development of epidermal growth factor receptor (EGFR)
inhibitors indicated that such inhibitors would be effective when given to patients with …

EGFR is a trans-membrane receptor tyrosine kinase that belongs to the HER family of
receptors. The EGFR family plays an essential role in normal organ development by …

Background Gemcitabine resistance (GR) is a significant clinical challenge in pancreatic
adenocarcinoma (PAAD) treatment. Macrophages in the tumor immune-microenvironment …

Epidermal growth factor receptor (EGFR) plays a key role in signal transduction pathways
associated with cell proliferation, growth, and survival. Its overexpression and aberrant …

Small molecule tyrosine kinase inhibitors (TKIs) are developed to block intracellular
signaling pathways in tumor cells, leading to deregulation of key cell functions such as …

Radiosensitization with antimetabolites has improved clinical outcome for patients with solid
malignancies, especially cancers of the GI tract, cervix, and head and neck. Fluorouracil …

Purpose: Gemcitabine-radiotherapy is a standard treatment for locally advanced pancreatic
cancer. Clinical data have shown that gemcitabine plus erlotinib is superior to gemcitabine …

The epidermal growth factor receptor (EGFR) is a target of new therapies in most
nonhematologic cancers. EGFR blockade alone may not be sufficient for the control of …

The Src gene product (Src) and the epidermal growth factor receptor (EGFR) are prototypes
of oncogene products and function primarily as a cytoplasmic non-receptor tyrosine kinase …

Purpose: Targeting the epidermal growth factor receptor (EGFR) is a validated approach to
treat cancer. In non–small cell lung cancer (NSCLC), EGFR contains somatic mutations in …